Chapter 3 Market and Technology Background
- Overview: Opioid Drugs
- Types of Opioids
- Receptor Targets of Opioid Drugs
- Mu Receptor
- Delta Receptor
- Kappa Receptor
- Significant Events Related to Opioid Misuse and Abuse
- Technology Advancements in Opioid Drugs
- Abuse-Deterrent Approaches
- Abuse-Deterrent Technologies
- Novel Drug Delivery Systems
- Therapeutic Applications of Opioid Drugs
- Cancer Pain Management
- Surgical Pain Management
- Opioid Use Disorder
- Prescription Drug Monitoring Programs (PDMPs)
Chapter 4 Market Dynamics
- Market Drivers
- Rising Prevalence of Chronic Pain
- Rise in Palliative Care for Patients Suffering from Pain
- New Opioid Formulation to Reduce the Risk of Abuse
- Increasing Incidence of Road Accidents and Surgical Procedures
- Market Restraints
- Widespread Misuse of Opioids
- Increasing Incidence of Death Related to Opioid Overdose
- Growing Number of Lawsuits against Opioid Manufacturers
Chapter 5 Market Breakdown by Product
- Global Market for Opioid Drugs by Product
- Buprenorphine
- Market Size and Forecast
- Market Analysis
- Fentanyl
- Market Size and Forecast
- Market Analysis
- Hydrocodone
- Market Size and Forecast
- Market Analysis
- Morphine
- Market Size and Forecast
- Market Analysis
- Oxycodone
- Market Size and Forecast
- Market Analysis
- Tramadol
- Market Size and Forecast
- Market Analysis
- Others
- Market Size and Forecast
- Market Analysis
Chapter 6 Market Breakdown by Region
- Global Market for Opioid Drugs by Region
- North America
- United States
- Canada and Mexico
- Europe
- Germany
- U.K.
- France
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
Chapter 7 Regulatory Environment
- Regulations in the U.S.
- New Drug Approvals
- The FDA Modernization Act of 1997
- New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
- Risk Evaluation and Mitigation Strategy (REMS)
- Schedules Under the Controlled Substances Act
- Federal Initiatives to Address Non-medical Use of Prescription Opioids
- FDA's Opioid Policy Work Plan
- CDC Guidelines for Prescribing Opioids for Chronic Pain
Chapter 8 Pipeline Analysis
- Overview of the Drug Development Process
- Pipeline Analysis of Opioid Drugs
Chapter 9 Competitive Landscape
- Current Market Scenario
- Key Strategies Adopted by Market Players
- Influence of Generic Drugs on the Global Opioid Drug Market
- Significant Industry Events and Developments
Chapter 10 Company Profiles
- ACURA PHARMACEUTICALS INC.
- Company Overview
- Product Portfolio
- ALLERGAN PLC
- Company Overview
- Financials
- Product Portfolio
- APOTEX INC.
- Company Overview
- Product Portfolio
- ASSERTIO THERAPEUTICS INC. (DEPOMED INC.)
- Company Overview
- Financials
- Product Portfolio
- Developments and Strategies
- BIODELIVERY SCIENCES INTERNATIONAL INC.
- Company Overview
- Financials
- Product Portfolio
- Developments and Strategies
- CIPHER PHARMACEUTICALS INC.
- Company Overview
- Product Portfolio
- COLLEGIUM PHARMACEUTICAL INC.
- Company Overview
- Product Portfolio
- DAIICHI SANKYO INC.
- Company Overview
- Product Portfolio
- EGALET CORP.
- Company Overview
- Product Portfolio
- ENDO INTERNATIONAL PLC
- Company Overview
- Financials
- Product Portfolio
- Developments and Strategy
- HIKMA PHARMACEUTICALS PLC
- Company Overview
- Product Portfolio
- INDIVIOR PLC
- Company Overview
- INSYS THERAPEUTICS INC.
- Company Overview
- Product Portfolio
- JOHNSON & JOHNSON
- Company Overview
- Product Portfolio
- KEMPHARM INC.
- Company Overview
- Product Portfolio
- LANNETT CO. INC.
- Company Overview
- Financials
- Product Portfolio
- LUPIN LTD.
- Company Overview
- Product Portfolio
- MALLINCKRODT
- Company Overview
- Product Portfolio
- MYLAN NV
- Company Overview
- Financials
- Product Portfolio
- Developments and Strategies
- OREXO AB
- Company Overview
- Product Portfolio
- PFIZER INC.
- Company Overview
- Product Portfolio
- Developments and Strategies
- PURDUE PHARMA LP
- Company Overview
- Product Portfolio
- Developments and Strategies
- PERNIX THERAPEUTICS
- Company Overview
- Product Portfolio
- Developments and Strategies
- SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
- Company Overview
- Financials
- Product Portfolio
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Company Overview
- Financials
- Product Portfolio
List of Tables
Summary Table: Global Opioid Drug Market, by Product, Through 2023
Table 1: Analgesic Effects of Drugs at Different Opioid Receptors
Table 2: Timeline of Selected FDA Activities and Events Related to Opioid Misuse and Abuse, 1911-2018
Table 3: FDA Approved Opioids with ADF Labeling
Table 4: Opioid Lawsuit Settlements, 2015-2027
Table 5: Global Opioid Drug Market, by Product, Through 2023
Table 6: Global Buprenorphine Drug Market, by Region, Through 2023
Table 7: Global Fentanyl Drug Market, by Region, Through 2023
Table 8: Global Hydrocodone Drug Market, by Region, Through 2023
Table 9: Global Morphine Drug Market, by Region, Through 2023
Table 10: Global Oxycodone Drug Market, by Region, Through 2023
Table 11: Global Tramadol Drug Market, by Region, Through 2023
Table 12: Global Market for Other Types of Opioid Drugs, by Region, Through 2023
Table 13: Global Opioid Drug Market, by Region, Through 2023
Table 14: North American Opioid Drug Market, by Product, Through 2023
Table 15: North American Opioid Drug Market, by Country, Through 2023
Table 16: Number of Prescriptions for Six of the Most Frequently Prescribed Opioids in Canada, 2012-2016
Table 17: European Opioid Drug Market, by Product, Through 2023
Table 18: European Opioid Drug Market, by Country, Through 2023
Table 19: Asia-Pacific Opioid Drug Market, by Product, Through 2023
Table 20: Asia-Pacific Opioid Drug Market, by Country, Through 2023
Table 21: South American Opioid Drug Market, by Product, Through 2023
Table 22: Middle East and African Opioid Drug Market, by Product, Through 2023
Table 23: List of ER/LA Opioid Drugs Subject to Opioid REMS, Branded Drugs, 2017
Table 24: List of ER/LA Opioid Drugs Subject to Opioid REMS, Generic Drugs, 2017
Table 25: Schedules Under the Controlled Substances Act
Table 26: Recent Initiatives to Control the Opioid Crisis in the U.S., 2018
Table 27: CDC Guidelines on Prescribing Opioids
Table 28: Opioid Drug Pipeline
Table 29: R&D Expenditures of Market Players, 2017
Table 30: Number of FDA Approvals (NDA and ANDA), 2005-2015
Table 31: Significant Industry Events in the Opioid Drug Market, 2015-2018
Table 32: Acura Pharmaceuticals: Opioid Drug Product Portfolio
Table 33: Allergan Plc: Opioid Drug Product Portfolio
Table 34: Apotex Inc.: Opioid Drug Product Portfolio
Table 35: Assertio Therapeutics: Opioid Drug Product Portfolio
Table 36: Biodelivery Sciences International Inc.: Opioid Drugs Product Portfolio
Table 37: Cipher Pharmaceuticals Inc.: Opioid Drugs Product Portfolio
Table 38: Collegium Pharmaceutical Inc.: Opioid Drug Product Portfolio
Table 39: Daiichi Sankyo Inc.: Opioid Drug Product Portfolio
Table 40: Egalet Corp.: Opioid Drugs Product Portfolio
Table 41: Endo International Plc: Opioid Drugs Product Portfolio
Table 42: Hikma Pharmaceuticals Plc: Opioid Drugs Product Portfolio
Table 43: Indivior Plc: Opioid Drug Product Portfolio
Table 44: Insys Therapeutics Inc.: Opioid Drug Product Portfolio
Table 45: Johnson & Johnson: Opioid Drug Product Portfolio
Table 46: KemPharm Inc.: Opioid Drugs Product Portfolio
Table 47: Lannett Co. Inc.: Opioid Drug Product Portfolio
Table 48: Lupin Ltd.: Opioid Drug Product Portfolio
Table 49: Mallinckrodt: Opioid Drug Product Portfolio
Table 50: Mylan NV: Opioid Drug Product Portfolio
Table 51: Orexo AB: Opioid Drug Product Portfolio
Table 52: Pfizer Inc.: Opioid Drugs Product Portfolio
Table 53: Purdue Pharma LP: Opioid Drug Product Portfolio
Table 54: Pernix Therapeutics: Opioid Drug Product Portfolio
Table 55: Sun Pharmaceuticals Industries Ltd.: Opioid Drugs Product Portfolio
Table 56: Teva Pharmaceutical Industries Ltd.: Opioid Drug Product Portfolio
Table 57: Acronyms Used in This Report
List of Figures
Summary Figure: Global Opioid Drug Market Share, by Product, 2017
Figure 1: Opioid Misuse Among People 12 or Older, by Age Group, 2015
Figure 2: Prescription Pain Relief Misuse Among People 12 or Older, by Age Group, 2015
Figure 3: Number of Drug Overdose Deaths in the U.S., 2010-2016
Figure 4: Global Opioid Drug Market Share, by Product, 2017
Figure 5: Global Buprenorphine Drug Market, 2017-2023
Figure 6: Global Buprenorphine Drug Market, by Region, 2017-2023
Figure 7: Global Fentanyl Drug Market, 2017-2023
Figure 8: Global Fentanyl Drug Market, by Region, 2017-2023
Figure 9: Global Hydrocodone Drug Market, 2017-2023
Figure 10: Global Hydrocodone Drug Market, by Region, 2017-2023
Figure 11: Global Morphine Drug Market, 2017-2023
Figure 12: Global Morphine Drug Market, by Region, 2017-2023
Figure 13: Global Oxycodone Drug Market, 2017-2023
Figure 14: Global Oxycodone Drug Market, by Region, 2017-2023
Figure 15: Global Tramadol Drug Market, 2017-2023
Figure 16: Global Tramadol Drug Market, by Region, 2017-2023
Figure 17: Global Market for Other Types of Opioid Drugs, 2017-2023
Figure 18: Global Market for Other Types of Opioid Drugs, by Region, 2017-2023
Figure 19: Global Opioid Drug Market Share, by Region, 2017
Figure 20: North American Opioid Drug Market Share, by Product, 2017
Figure 21: North American Opioid Drug Market Share, by Country, 2017
Figure 22: U.S. Opioid Drug Market, 2017-2023
Figure 23: Total Number of Opioid Prescriptions Dispensed, U.S, 2010-2017
Figure 24: Number of Drug Overdose Deaths, U.S., 2010-2016
Figure 25: Canadian and Mexican Market for Opioid Drugs, 2017-2023
Figure 26: European Opioid Drug Market Share, by Product, 2017
Figure 27: European Opioid Drug Market Share, by Country, 2017
Figure 28: German Opioid Drug Market, 2017-2023
Figure 29: U.K. Opioid Drug Market, 2017-2023
Figure 30: French Opioid Drug Market, 2017-2023
Figure 31: Rest of European Market for Opioid Drugs, 2017-2023
Figure 32: Asia-Pacific Opioid Drug Market Share, by Product, 2017
Figure 33: Asia-Pacific Opioid Drug Market Share, by Country, 2017
Figure 34: Japanese Opioid Drug Market, 2017-2023
Figure 35: Chinese Opioid Drug Market, 2017-2023
Figure 36: Indian Opioid Drug Market, 2017-2023
Figure 37: Rest of Asia-Pacific Opioid Drug Market, 2017-2023
Figure 38: South American Opioid Drug Market, 2017-2023
Figure 39: South American Opioid Drug Market Share, by Product, 2017
Figure 40: Middle East and African Market for Opioid Drugs, 2017-2023
Figure 41: Middle East and African Opioid Drug Market Share, by Product, 2017
Figure 42: Allergan Plc: Annual Revenue, 2013-2017
Figure 43: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 44: Assertio Therapeutics: Revenue, 2013-2017
Figure 45: Biodelivery Sciences International Inc.: Annual Revenue, 2013-2017
Figure 46: Endo International Plc: Revenue, 2013-2017
Figure 47: Endo International Plc: Revenue Share, by Business Unit, 2017
Figure 48: Lannett Co. Inc.: Financial Performance, 2015-2017
Figure 49: Mylan NV: Financial Performance, 2014-2017
Figure 50: Mylan NV: Revenue Share, by Region, 2017
Figure 51: Sun Pharmaceuticals Industries Ltd.: Financial Performance, 2015-2017
Figure 52: Teva Pharmaceutical Industries Ltd.: Financial Performance, 2015-2017
Figure 53: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 54: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
